Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.03 – $2.79
1% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $540.0K | $756.0K | $849.0K |
| Gross profit | $0 | $0 | $0 | −$540.0K | −$756.0K | −$849.0K |
| Gross margin | — | — | — | — | — | — |
| R&D | $7.9M | $8.5M | $30.2M | $47.0M | $67.8M | $71.5M |
| Operating income | −$9.9M | −$10.1M | −$41.2M | −$71.4M | −$91.4M | −$95.2M |
| EBITDA | −$824.0K | −$12.0M | −$67.4M | −$69.3M | −$84.5M | −$93.2M |
| Net income | −$10.7M | −$12.0M | −$67.9M | −$71.5M | −$86.1M | −$95.5M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -60.66 | -1.05 | -2.36 | -2.48 | -1.98 | -1.45 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $14M | $-0.29 | $-0.29–$-0.29 | 1 |
| 2027 | $18M | $-0.31 | $-0.31–$-0.31 | 1 |
| 2028 | $54M | $-0.19 | $-0.25–$-0.13 | 2 |
| 2029 | $146M | $-0.04 | $-0.04–$-0.04 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds IOBT.
No tracked institution reports a position in IOBT as of their last filing.
No one on the platform has traded IOBT yet.
| $59M |
| — |
| KPTIKaryopharm Therapeutics Inc. | $10.09 | -1.22% | $229M | — |
| NRXPNRx Pharmaceuticals, Inc. | $4.00 | +7.24% | $69M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.